Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL® at ASCO Breast Cancer Symposium
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results
September 23, 2015 11:00 AM EDTBrean Capital reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX), and raised the price target to $55.00 (from $45.00), following announced positive top-line results from HTX-011. Analyst Jonathan Aschoff projects HTX-011 to have a higher price, and drive significant value.
Aschoff commented, "Yesterday, Heron announced positive top-line results from its Phase 2 trial of HTX-011 for the treatment of post-operative pain after bunionectomy. This randomized, placebo-controlled, double-blind, Phase 2 trial evaluated the... More
Heron Therapeutics (HRTX) to Present SUSTOL Data as CINV Prevention at ASCO 2015 Breast Cancer Symposium
September 22, 2015 8:06 AM EDTHeron Therapeutics (NASDAQ: HRTX) announced that data from Herons recently completed MAGIC Study of SUSTOL (granisetron) Injection, extended release, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC), will be presented at the American Society of Clinical... More
